0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Review |

Therapeutic Advances in Localized Pancreatic Cancer

Susan Tsai, MD, MHS1,2; Douglas B. Evans, MD1,2
[+] Author Affiliations
1The Pancreatic Cancer Program, The Medical College of Wisconsin, Milwaukee
2Department of Surgery, The Medical College of Wisconsin, Milwaukee
JAMA Surg. 2016;151(9):862-868. doi:10.1001/jamasurg.2016.1113.
Text Size: A A A
Published online

Importance  It is estimated that pancreatic cancer (PC) will become the second leading cause of cancer-related death in the United States by 2030.

Observations  Clinical and preclinical data support the understanding that PC metastases occur early in the pathogenesis of this disease, even before the primary tumor can be detected. This has important implications for the clinical management of patients with localized PC, as surgery alone is unlikely to be curative for most patients. The delivery of postoperative adjuvant therapy is problematic in this disease because of the magnitude of the operation needed to remove the primary tumor, which can affect patient recovery and delay (sometimes indefinitely) the delivery of systemic therapy. For these reasons, the use of chemotherapy and/or chemoradiation prior to surgery (neoadjuvant therapy) is increasingly recognized as the preferred strategy for treatment sequencing. Neoadjuvant therapy is recommended for patients with borderline resectable PC and, at some centers, neoadjuvant therapy has been extended to patients with resectable PC as well. Importantly, therapeutic advances in multidrug systemic therapy and radiation therapy have already been adopted in the neoadjuvant setting where treatment toxicity will not be compounded by surgical recovery. In addition, the use of local-regional therapies in highly selected patients with locally advanced PC, following a prolonged period of induction systemic therapy, will be an area of intense scrutiny. Future improvements in diagnostic biomarkers may allow for real-time sequencing of multimodality therapy for individual patients based on a more accurate and timely assessment of treatment response.

Conclusions and Relevance  Neoadjuvant treatment sequencing allows patients to receive multimodality therapy in a manner that prioritizes early exposure to systemic therapy to maximize the treatment of micrometastatic disease in an immune-competent host prior to surgical intervention. Patients who complete all intended neoadjuvant therapy, including surgery, experience an overall survival benefit that is unmatched by a surgery-first approach.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Figures

Place holder to copy figure label and caption
Figure.
Sequencing of Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer Outside of the Context of a Clinical Trial (Trial Usually Preferred)

Future clinical trials will likely incorporate all intended systemic therapy and chemoradiation prior to surgery, for reasons that span both host/tumor biology and practical considerations. The delivery of postoperative adjuvant therapy is difficult and, in some patients of advanced age, made more difficult with induction therapy prior to surgery. With improved techniques for the rapid assessment of treatment response, we may enter an exciting time in the management of localized pancreatic cancer that allows for the application of tumor/patient-specific systemic therapy (with or without chemoradiation) followed by the selective application of surgery to responding patients. CA indicates carbohydrate antigen; CT, computed tomography; EUS, endoscopic ultrasonography; FNA, fine-needle aspiration; M-F, Monday through Friday.

Graphic Jump Location

Tables

References

Correspondence

CME


You need to register in order to view this quiz.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

3,798 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();